| Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity JI Mayordomo, T Zorina, WJ Storkus, L Zitvogel, C Celluzzi, LD Falo, ... Nature medicine 1 (12), 1297-1302, 1995 | 1375 | 1995 |
| The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. A Sette, A Vitiello, B Reherman, P Fowler, R Nayersina, WM Kast, ... Journal of immunology (Baltimore, Md.: 1950) 153 (12), 5586-5592, 1994 | 1095 | 1994 |
| Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells MCW Feltkamp, HL Smits, MPM Vierboom, RP Minnaar, BM De Jongh, ... European journal of immunology 23 (9), 2242-2249, 1993 | 1016 | 1993 |
| Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells S Weijzen, P Rizzo, M Braid, R Vaishnav, SM Jonkheer, A Zlobin, ... Nature medicine 8 (9), 979-986, 2002 | 749 | 2002 |
| Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells DI Gabrilovich, MP Velders, EM Sotomayor, WM Kast The Journal of Immunology 166 (9), 5398-5406, 2001 | 694 | 2001 |
| Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A* 0201-binding peptides. ME Ressing, A Sette, RM Brandt, J Ruppert, PA Wentworth, M Hartman, ... Journal of immunology (Baltimore, Md.: 1950) 154 (11), 5934-5943, 1995 | 524 | 1995 |
| Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. SH Van Der Burg, MJ Visseren, RM Brandt, WM Kast, CJ Melief Journal of immunology (Baltimore, Md.: 1950) 156 (9), 3308-3314, 1996 | 522 | 1996 |
| Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro TNM Schumacher, MT Heemels, JJ Neefjes, WM Kast, CJM Melief, ... Cell 62 (3), 563-567, 1990 | 490 | 1990 |
| Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. WM Kast, RM Brandt, J Sidney, JW Drijfhout, RT Kubo, HM Grey, ... Journal of immunology (Baltimore, Md.: 1950) 152 (8), 3904-3912, 1994 | 463 | 1994 |
| Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model HL Greenstone, JD Nieland, KE De Visser, MLH De Bruijn, R Kirnbauer, ... Proceedings of the National Academy of Sciences 95 (4), 1800-1805, 1998 | 458 | 1998 |
| Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. WM Kast, L Roux, J Curren, HJ Blom, AC Voordouw, RH Meloen, ... Proceedings of the National Academy of Sciences 88 (6), 2283-2287, 1991 | 437 | 1991 |
| A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive L Muderspach, S Wilczynski, L Roman, L Bade, J Felix, LA Small, ... Clinical Cancer Research 6 (9), 3406-3416, 2000 | 436 | 2000 |
| T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer M Mercader, BK Bodner, MT Moser, PS Kwon, ESY Park, RG Manecke, ... Proceedings of the National Academy of Sciences 98 (25), 14565-14570, 2001 | 425 | 2001 |
| Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. RE Toes, R Offringa, RJ Blom, CJ Melief, WM Kast Proceedings of the National Academy of Sciences 93 (15), 7855-7860, 1996 | 408 | 1996 |
| Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes WM Kast, R Offringa, PJ Peters, AC Voordouw, RH Meloen, AJ van der Eb, ... Cell 59 (4), 603-614, 1989 | 397 | 1989 |
| Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy U Keilholz, J Weber, JH Finke, DI Gabrilovich, WM Kast, ML Disis, ... Journal of immunotherapy 25 (2), 97-138, 2002 | 382 | 2002 |
| Mechanisms used by human papillomaviruses to escape the host immune response S Kanodia, LM Fahey, WM Kast Current cancer drug targets 7 (1), 79-89, 2007 | 379 | 2007 |
| Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, DC DJ Adelstein, JA Ridge, ML Gillison, AK Chaturvedi, G D'Souza, ... Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2009 | 351 | 2009 |
| In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 JGA Houbiers, HW Nijman, SH Van Der Burg, JW Drijfhout, P Kenemans, ... European Journal of Immunology 23 (9), 2072-2077, 1993 | 332 | 1993 |
| Peptide selection by MHC class I molecules TNM Schumacher, MLHD Bruijn, LN Vernie, WM Kast, CJM Melief, ... Nature 350 (6320), 703-706, 1991 | 329 | 1991 |
